Alyeska Investment Group L.P. raised its position in shares of Jounce Therapeutics Inc (NASDAQ:JNCE) by 43.7% in the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 262,105 shares of the company’s stock after purchasing an additional 79,683 shares during the quarter. Alyeska Investment Group L.P. owned 0.81% of Jounce Therapeutics worth $4,084,000 at the end of the most recent quarter.
Other large investors have also recently added to or reduced their stakes in the company. Macquarie Group Ltd. purchased a new stake in shares of Jounce Therapeutics during the 3rd quarter valued at about $124,000. American International Group Inc. boosted its holdings in shares of Jounce Therapeutics by 132.2% during the 3rd quarter. American International Group Inc. now owns 9,559 shares of the company’s stock valued at $149,000 after acquiring an additional 5,442 shares during the last quarter. TIAA CREF Investment Management LLC purchased a new stake in shares of Jounce Therapeutics during the 1st quarter valued at about $229,000. Teachers Advisors LLC boosted its holdings in shares of Jounce Therapeutics by 26.4% during the 2nd quarter. Teachers Advisors LLC now owns 11,231 shares of the company’s stock valued at $158,000 after acquiring an additional 2,347 shares during the last quarter. Finally, Ark Investment Management LLC boosted its holdings in shares of Jounce Therapeutics by 558.9% during the 2nd quarter. Ark Investment Management LLC now owns 11,932 shares of the company’s stock valued at $167,000 after acquiring an additional 10,121 shares during the last quarter. Institutional investors and hedge funds own 47.55% of the company’s stock.
Shares of Jounce Therapeutics Inc (JNCE) opened at $13.71 on Wednesday. Jounce Therapeutics Inc has a 1-year low of $11.05 and a 1-year high of $29.29.
Jounce Therapeutics (NASDAQ:JNCE) last announced its quarterly earnings results on Monday, November 13th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.12. The firm had revenue of $18.10 million for the quarter, compared to the consensus estimate of $20.00 million. Jounce Therapeutics had a negative net margin of 2.03% and a negative return on equity of 1.39%. The business’s revenue was up 7.1% on a year-over-year basis. sell-side analysts expect that Jounce Therapeutics Inc will post -0.86 earnings per share for the current year.
A number of analysts have recently issued reports on JNCE shares. J P Morgan Chase & Co set a $28.00 price target on shares of Jounce Therapeutics and gave the company a “buy” rating in a report on Monday, November 13th. Robert W. Baird reaffirmed a “buy” rating and set a $30.00 price target on shares of Jounce Therapeutics in a report on Friday, November 10th. Finally, Zacks Investment Research downgraded shares of Jounce Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, August 15th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Jounce Therapeutics presently has a consensus rating of “Buy” and an average price target of $23.67.
WARNING: “Alyeska Investment Group L.P. Has $4.08 Million Holdings in Jounce Therapeutics Inc (JNCE)” was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece of content on another publication, it was illegally stolen and reposted in violation of United States & international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.dispatchtribunal.com/2017/12/13/alyeska-investment-group-l-p-has-4-08-million-holdings-in-jounce-therapeutics-inc-jnce.html.
About Jounce Therapeutics
Jounce Therapeutics, Inc is a clinical stage immunotherapy company. The Company is engaged in transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within tumors to prioritize targets, and then identifies related biomarkers designed to match the right therapy to the right patient.
Receive News & Ratings for Jounce Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jounce Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.